Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and women's health, including endometriosis. Drugs have been designed to inhibit STS, e.g., Irosustat, as innovative dual-targeting aromatase-steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through microtubule disruption. The aryl sulfamate pharmacophore is highly versatile, operating via three distinct mechanisms of action, and imbues attractive pharmaceutical properties. This Perspective gives a personal view of the work leading both to the therapeutic concepts and these drugs, their current status, and how they might develop in the future.

Original publication

DOI

10.1021/acs.jmedchem.5b00386

Type

Journal article

Journal

J Med Chem

Publication Date

08/10/2015

Volume

58

Pages

7634 - 7658

Keywords

Animals, Antineoplastic Agents, Aromatase Inhibitors, Breast Neoplasms, Drug Discovery, Endometriosis, Estrone, Female, Humans, Male, Molecular Targeted Therapy, Prostatic Neoplasms, Steryl-Sulfatase, Sulfonic Acids, Tubulin Modulators